Login to Your Account



Amylin, Lilly File For Approval Of Exenatide In Type II Diabetes

By Kim Coghill


Thursday, July 1, 2004
Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. filed a new drug application seeking approval of exenatide as a treatment for Type II diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription